FDI In India’s Medical Devices Sector Plunges, Experts Blame Price Controls
Executive Summary
FDI in India's medtech sector has plunged to levels last seen before investment in the sector was liberalized and the Indian association representing global medical technology firms says government-imposed price controls are to blame.
You may also be interested in...
Industry Advocacy Group Goes Global After Device Tax Repeal
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.
Multinational Medtech Firms Accuse Indian Peers Of Exaggerating Imports In Bid For Higher Duties
Global medical device manufacturers have accused their Indian counterparts of exaggerating medtech import numbers to get the government to hike import duties and shield them from foreign competition.
India Strikes Pricing Blow To Knees After Stent Cuts
Six months after imposing stiff price controls on cardiac stents, India’s government slashed costs of knee implants by nearly 70%, saying the action was necessary to end “unethical profiteering.”